Related CAS #
1415126-69-0 (phosphate); 1211231-85-4 (trifluoroacetate); 1211231-53-6 (HCl); 1211231-76-3 (free base)
Synonym
Oxicodegol trifluoroacetate; NKTR181 trifluoroacetate; NKTR 181 trifluoroacetate; NKTR-181 trifluoroacetate
IUPAC/Chemical Name
Morphinan-14-ol, 4,5-epoxy-6-(3,6,9,12,15,18-hexaoxanonadec-1-yloxy)-3-methoxy-17-methyl-, (5alpha,6alpha)-, 2,2,2-trifluoroacetate (1:1)
InChi Key
VLPVFQRJECMGMK-HQDKYZDVSA-N
InChi Code
InChI=1S/C33H48F3NO11/c1-37-9-8-31-27-23-4-5-24(40-3)28(27)47-29(31)25(6-7-32(31,26(37)22-23)48-30(38)33(34,35)36)46-21-20-45-19-18-44-17-16-43-15-14-42-13-12-41-11-10-39-2/h4-5,25-26,29H,6-22H2,1-3H3/t25-,26-,29+,31+,32-/m1/s1
SMILES Code
CN(CC1)[C@H]2[C@]3(OC(C(F)(F)F)=O)CC[C@@H](OCCOCCOCCOCCOCCOCCOC)[C@@]4([H])[C@]31C5=C(O4)C(OC)=CC=C5C2
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
691.74
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Henningfield JE, Gudin J, Rauck R, Gimbel J, Tagliaferri M, Doberstein SK, Di Fonzo C, Lu L, Katz N, Siddhanti S, Schnoll S. Measuring Opioid Withdrawal in a Phase 3 Study of a New Analgesic, NKTR-181 (Oxycodegol), in Patients with Moderate to Severe Chronic Low Back Pain. Pain Med. 2020 Aug 1;21(8):1553-1561. doi: 10.1093/pm/pnz326. PMID: 32150255; PMCID: PMC7530570.
2: Ge X, Henningfield JE, Siddhanti S, Jobes J, Lu L, Xie S, Ziola M, Kelsh D, Vince B, Di Fonzo CJ, Tagliaferri M, Zalevsky J, Doberstein SK, Hoch U, Eldon MA. Human Abuse Potential of Oral NKTR-181 in Recreational Opioid Users: A Randomized, Double-Blind, Crossover Study. Pain Med. 2020 Feb 1;21(2):e114-e126. doi: 10.1093/pm/pnz232. PMID: 31553457.
3: Gudin J, Rauck R, Argoff C, Agaiby E, Gimbel J, Katz N, Doberstein SK, Tagliaferri M, Tagliaferri M, Potts J, Wild J, Lu L, Siddhanti S, Hale M, Markman J. Long-term Safety and Tolerability of NKTR-181 in Patients with Moderate to Severe Chronic Low Back Pain or Chronic Noncancer Pain: A Phase 3 Multicenter, Open-Label, 52-Week Study (SUMMIT-08 LTS). Pain Med. 2020 Nov 7;21(7):1347-1356. doi: 10.1093/pm/pnz169. PMID: 31361019; PMCID: PMC7372935.
